Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical and Translational Oncology
Erschienen in: Clinical and Translational Oncology 7/2014

01.07.2014 | Educational Series – Red Series

Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma

verfasst von: Z. Yuan, W.-T. Li, X.-D. Ye, H.-Y. Zhu, W.-J. Peng

Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

The established and adapted image biomarkers based on size for tumor burden measurement continue to be applied to hepatocellular carcinoma (HCC) as size measurement can easily be used in clinical practice. However, in the setting of novel targeted therapies and liver directed treatments, simple tumor anatomical changes can be less informative and usually appear later than biological changes. Functional magnetic resonance imaging (MRI) has a potential to be a promising technique for assessment of HCC response to therapy. In this review, we discuss various functional MRI biomarkers that play an increasingly important role in evaluation of HCC response after treatment.
Literatur
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMed
3.
Alsina AE. Liver transplantation for hepatocellular carcinoma. Cancer Control. 2010;17:83–6.PubMed
4.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.CrossRefPubMed
5.
Rosen MA. Use of modified RECIST criteria to improve response assessment in targeted therapies: challenges and opportunities. Cancer Biol Ther. 2010;9:20–2.CrossRefPubMed
6.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefPubMed
7.
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol. 2001;35:421–30.CrossRefPubMed
8.
Iwazawa J, Ohue S, Hashimoto N, Yasumasa K, Abe H, Mitani T. Bevacizumab-induced hypovascular hepatocellular carcinoma treated by transarterial chemoembolization in a patient with metastatic colon cancer. J Vasc Interv Radiol. 2010;21:412–4.CrossRefPubMed
9.
Kudo M. Imaging blood flow characteristics of hepatocellular carcinoma. Oncology. 2002;62:48–56.CrossRefPubMed
10.
Pandharipande PV, Krinsky GA, Rusinek H, Lee VS. Perfusion imaging of the liver: current challenges and future goals. Radiology. 2005;234:661–73.CrossRefPubMed
11.
Rao SX, Chen CZ, Liu H, Zeng MS, Qu XD. Three-dimensional whole-liver perfusion magnetic resonance imaging in patients with hepatocellular carcinomas and colorectal hepatic metastases. BMC Gastroenterol. 2013;13:53.PubMedCentralCrossRefPubMed
12.
Hagiwara M, Rusinek H, Lee VS, Losada M, Bannan MA, Krinsky GA, et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging—initial experience. Radiology. 2008;246:926–34.CrossRefPubMed
13.
Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003;21:3955–64.CrossRefPubMed
14.
Wang J, Chen LT, Tsang YM, Liu TW, Shih TT. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol. 2004;183:713–9.CrossRefPubMed
15.
Miyazaki K, Collins DJ, Walker-Samuel S, Taylor JN, Padhani AR, Leach MO, et al. Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol. 2008;18:1414–21.CrossRefPubMed
16.
Totman JJ, O’Gorman RL, Kane PA, Karani JB. Comparison of the hepatic perfusion index measured with gadolinium-enhanced volumetric MRI in controls and in patients with colorectal cancer. Br J Radiol. 2005;78:105–9.CrossRefPubMed
17.
Wang D, Bangash AK, Rhee TK, Woloschak GE, Paunesku T, Salem R, et al. Liver tumors: monitoring embolization in rabbits with VX2 tumors—transcatheter intraarterial first-pass perfusion MR imaging. Radiology. 2007;245:130–9.CrossRefPubMed
18.
Larson AC, Wang D, Atassi B, Sato KT, Ryu RK, Lewandowski RJ, et al. Transcatheter intraarterial perfusion: MR monitoring of chemoembolization for hepatocellular carcinoma—feasibility of initial clinical translation. Radiology. 2008;246:964–71.CrossRefPubMed
19.
Gaba RC, Wang D, Lewandowski RJ, Ryu RK, Sato KT, Kulik LM, et al. Four-dimensional transcatheter intraarterial perfusion MR imaging for monitoring chemoembolization of hepatocellular carcinoma: preliminary results. J Vasc Interv Radiol. 2008;19:1589–95.PubMedCentralCrossRefPubMed
20.
Katada Y, Shukuya T, Kawashima M, Nozaki M, Imai H, Natori T, et al. A comparative study between arterial spin labeling and CT perfusion methods on hepatic portal venous flow. Jpn J Radiol. 2012;30:863–9.CrossRefPubMed
21.
Weinreb JC. Which study when? Is gadolinium-enhanced MR imaging safer than iodine-enhanced CT? Radiology. 2008;249:3–8.CrossRefPubMed
22.
Sahani DV, Holalkere NS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue—initial experience. Radiology. 2007;243:736–43.CrossRefPubMed
23.
24.
Zech CJ, Reiser MF, Herrmann KA. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis. 2009;27:114–24.CrossRefPubMed
25.
Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009;250:466–73.CrossRefPubMed
26.
Goshima S, Kanematsu M, Kondo H, Yokoyama R, Tsuge Y, Shiratori Y, et al. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging. 2008;27:834–9.CrossRefPubMed
27.
Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006;17:505–12.CrossRefPubMed
28.
Rhee TK, Naik NK, Deng J, Atassi B, Mulcahy MF, Kulik LM, et al. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol. 2008;19:1180–6.CrossRefPubMed
29.
Schraml C, Schwenzer NF, Martirosian P, Bitzer M, Lauer U, Claussen CD, et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol. 2009;193:W301–7.CrossRefPubMed
30.
Yuan Z, Ye XD, Dong S, Xu LC, Xu XY, Liu SY, et al. Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol. 2010;75:e9–14.CrossRefPubMed
31.
Kubota K, Yamanishi T, Itoh S, Murata Y, Miyatake K, Yasunami H, et al. Role of diffusion-weighted imaging in evaluating therapeutic efficacy after transcatheter arterial chemoembolization for hepatocellular carcinoma. Oncol Rep. 2010;24:727–32.CrossRefPubMed
32.
Mannelli L, Kim S, Hajdu CH, Babb JS, Taouli B. Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: prediction and assessment of response to transarterial chemoembolization preliminary experience. Eur J Radiol. 2013;82:577–82.CrossRefPubMed
33.
Yuan Z, Li WT, Peng WJ. Pre-treatment apparent diffusion coefficient is imaging biomarker for prediction of response to chemoembolization in hepatocellular carcinoma. Eur J Radiol. doi:10.​1016/​j.​ejrad.​2013.​08.​009.
34.
Dong S, Ye XD, Yuan Z, Xu LC, Xiao XS. Relationship of apparent diffusion coefficient to survival for patients with unresectable primary hepatocellular carcinoma after chemoembolization. Eur J Radiol. 2012;81:472–7.CrossRefPubMed
35.
Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102–25.PubMedCentralPubMed
36.
Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology. 2011;260(3):752–61.CrossRefPubMed
37.
Bonekamp S, Li Z, Geschwind JF, Halappa VG, Corona-Villalobos CP, Reyes D, et al. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria. Radiology. 2013;268(2):420–30.CrossRefPubMed
38.
Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, et al. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013;268(2):431–9.
39.
Murphy M, Loosemore A, Clifton AG, Howe FA, Tate AR, Cudlip SA, et al. The contribution of proton magnetic resonance spectroscopy (1HMRS) to clinical brain tumour diagnosis. Br J Neurosurg. 2002;16:329–34.CrossRefPubMed
40.
Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology. 2002;222:715–21.CrossRefPubMed
41.
Möller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H, Pilatus U, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology. 2002;44:371–81.CrossRefPubMed
42.
Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging—clinicopathologic study. Radiology. 1999;213:473–80.CrossRefPubMed
43.
Bolan PJ, DelaBarre L, Baker EH, Merkle H, Everson LI, Yee D, et al. Eliminating spurious lipid sidebands in 1H MRS of breast lesions. Magn Reson Med. 2002;48:215–22.CrossRefPubMed
44.
Yeung DK, Cheung HS, Tse GM. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy—initial results. Radiology. 2001;220:40–6.CrossRefPubMed
45.
Allen JR, Prost RW, Griffith OW, Erickson SJ, Erickson BA. In vivo proton (H1) magnetic resonance spectroscopy for cervical carcinoma. Am J Clin Oncol. 2001;24:522–9.CrossRefPubMed
46.
Chen CY, Li CW, Kuo YT, Jaw TS, Wu DK, Jao JC, et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants—initial experience. Radiology. 2006;239:448–56.CrossRefPubMed
47.
Griffiths JR, Tate AR, Howe FA, Stubbs M, Group on MRS Application to Cancer. Magnetic resonance spectroscopy of cancer—practicalities of multi-centre trials and early results in non-Hodgkin’s lymphoma. Eur J Cancer. 2002;38:2085–93.CrossRefPubMed
48.
Ross B, Marshall V, Smith M, Bartlett S, Freeman D. Monitoring response to chemotherapy of intact human tumours by 31P nuclear magnetic resonance. Lancet. 1984;1:641–6.CrossRefPubMed
49.
Bizzi A, Movsas B, Tedeschi G, Phillips CL, Okunieff P, Alger JR, et al. Response of non-Hodgkin lymphoma to radiation therapy: early and long-term assessment with H-1 MR spectroscopic imaging. Radiology. 1995;194:271–6.PubMed
50.
Kurhanewicz J, Vigneron DB, Hricak H, Parivar F, Nelson SJ, Shinohara K, et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology. 1996;200:489–96.PubMed
51.
Schwarz AJ, Maisey NR, Collins DJ, Cunningham D, Huddart R, Leach MO. Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br J Radiol. 2002;75:959–66.PubMed
52.
Longo R, Ricci C, Masutti F, Vidimari R, Crocé LS, Bercich L, et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol. 1993;28:297–302.CrossRefPubMed
53.
Cho SG, Kim MY, Kim HJ, Kim YS, Choi W, Shin SH, et al. Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings. Radiology. 2001;221:740–6.CrossRefPubMed
54.
Lim AK, Patel N, Hamilton G, Hajnal JV, Goldin RD, Taylor-Robinson SD. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology. 2003;37:788–94.CrossRefPubMed
55.
Menon DK, Sargentoni J, Taylor-Robinson SD, Bell JD, Cox IJ, Bryant DJ, et al. Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances. Hepatology. 1995;21:417–27.PubMed
56.
Taylor-Robinson SD, Sargentoni J, Bell JD, Saeed N, Changani KK, Davidson BR, et al. In vivo and in vitro hepatic 31P magnetic resonance spectroscopy and electron microscopy of the cirrhotic liver. Liver. 1997;17:198–209.CrossRefPubMed
57.
Lim AK, Patel N, Gedroyc WM, Blomley MJ, Hamilton G, Taylor-Robinson SD. Hepatocellular adenoma: diagnostic difficulties and novel imaging techniques. Br J Radiol. 2002;75:695–9.PubMed
58.
Dixon RM. NMR studies of phospholipid metabolism in hepatic lymphoma. NMR Biomed. 1998;11:370–9.CrossRefPubMed
59.
Bell JD, Bhakoo KK. Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours. NMR Biomed. 1998;11:354–9.CrossRefPubMed
60.
Schilling A, Gewiese B, Berger G, Boese-Landgraf J, Fobbe F, Stiller D, et al. Liver tumors: follow-up with P-31 MR spectroscopy after local chemotherapy and chemoembolization. Radiology. 1992;182:887–90.PubMed
61.
Kuo YT, Li CW, Chen CY, Jao J, Wu DK, Liu GC. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging. 2004;19:598–604.CrossRefPubMed
62.
Wu B, Peng WJ, Wang PJ, Gu YJ, Li WT, Zhou LP, et al. In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization. Chin Med Sci J. 2006;21:258–64.PubMed
63.
Bian DJ, Xiao EH, Hu DX, Chen XY, Situ WJ, Yuan SW, et al. Magnetic resonance spectroscopy on hepatocellular carcinoma after transcatheter arterial chemoembolization. Chin J Cancer. 2010;29:198–201.CrossRefPubMed
64.
Soper R, Himmelreich U, Painter D, Somorjai RL, Lean CL, Dolenko B, et al. Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spectroscopy and a statistical classification strategy. Pathology. 2002;34:417–22.CrossRefPubMed
65.
Mahmood U, Alfieri AA, Ballon D, Traganos F, Koutcher JA. In vitro and in vivo 31P nuclear magnetic resonance measurements of metabolic changes post radiation. Cancer Res. 1995;55:1248–54.PubMed
66.
Murata O, Sakurai H, Mitsuhashi N, Hasegawa M, Yamakawa M, Kurosaki H, et al. 31P NMR spectroscopy can predict the optimum interval between fractionated irradiation doses. Anticancer Res. 1998;18:4297–301.PubMed
67.
Li SJ, Jin GY, Fish BL, Moulder JE. Correlation of radiobiological assays of hypoxic fraction with phosphorus-31 magnetic resonance spectroscopy across multiple tumor lines. Radiat Res. 1995;143:45–53.CrossRefPubMed
68.
Meyerhoff DJ, Karczmar GS, Valone F, Venook A, Matson GB, Weiner MW. Hepatic cancers and their response to chemoembolization therapy: quantitative image-guided 31P magnetic resonance spectroscopy. Invest Radiol. 1992;27:456–64.CrossRefPubMed
69.
Yuan Z, Ye XD, Dong S, Xu LC, Xiao XS. Evaluation of early imaging response after chemoembolization of hepatocellular carcinoma by phosphorus-31 magnetic resonance spectroscopy—initial experience. J Vasc Interv Radiol. 2011;22:1166–73.CrossRefPubMed
70.
Chmelík M, Schmid AI, Gruber S, Szendroedi J, Krssák M, Trattnig S, et al. Three-dimensional high-resolution magnetic resonance spectroscopic imaging for absolute quantification of 31p metabolites in human liver. Magn Reson Med. 2008;60:796–802.CrossRefPubMed
71.
Tosner Z, Dezortova M, Tintera J, Hájek M. Application of two-dimensional CSI for absolute quantification of phosphorus metabolites in the human liver. MAGMA. 2001;13:40–6.CrossRefPubMed
Metadaten
Titel
Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma
verfasst von
Z. Yuan
W.-T. Li
X.-D. Ye
H.-Y. Zhu
W.-J. Peng
Publikationsdatum
01.07.2014
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 7/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1147-5

Weitere Artikel der Ausgabe 7/2014

Clinical and Translational Oncology 7/2014 Zur Ausgabe

Research Article

Proteomic analysis of differentially expressed proteins in 5-fluorouracil-treated human breast cancer MCF-7 cells

Research Article

The significant increase and dynamic changes of the myeloid-derived suppressor cells percentage with chemotherapy in advanced NSCLC patients

Research Article

Recombinant human endostatin combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancer

Research Article

Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine

Research Article

Increased expression of α5β1-integrin is a prognostic marker for patients with gastric cancer

Research Article

Temporal trends of incidence and survival of sarcoma of digestive tract including Gastrointestinal Stromal Tumours (GIST) in two areas of the north-east of Spain in the period 1981–2005: a population-based study

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen